Vildagliptin

Таблетки By prescription

Hypoglycaemic agent. Vildagliptin is a representative of the class of stimulators of pancreatic islet apparatus, selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4).

Vildagliptin

Important

One tablet of the drug Vildagliptin contains 50 mg of the active substance vildagliptin, which normalises blood glucose content. Vildagliptin belongs to the group of medicines for the treatment of diabetes mellitus; hypoglycaemic agents, except insulins; dipeptidyl peptidase-4 (DDP-4) inhibitors. Vildagliptin may be prescribed to you as a single medicine or in combination with other medicines to control blood sugar levels in type 2 diabetes. It is important to take Vildagliptin with the recommended diet and exercise. If you have any questions about why you are prescribed this medicine, please contact your doctor.

Indications

The medicinal product Vildagliptin is indicated for use in adult patients with type 2 diabetes mellitus (in combination with diet therapy and exercise):

- as monotherapy in case of ineffectiveness of diet therapy and exercise in patients with contraindications to use/intolerance to metformin or in case of ineffectiveness of metformin;

- in combination with metformin as initial drug therapy in case of insufficient effectiveness of diet therapy and exercise;

- as part of two-component combination therapy: with metformin or thiazolidinedione, or with insulin in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs;

- as part of two-component combination therapy with sulfonylurea derivatives in patients with insufficient glycaemic control against the maximum tolerated dose of a sulfonylurea derivative or in the presence of contraindications to the use/intolerance of metformin;

- as part of triple combination therapy: in combination with sulfonylurea derivatives and metformin, in patients who have previously received therapy with sulfonylurea derivatives and metformin against the background of diet therapy and exercise and have not achieved adequate glycaemic control;

- as part of triple combination therapy: in combination with insulin and metformin, in patients who previously received insulin in a stable dose and metformin on the background of diet therapy and exercise, and have not achieved adequate glycaemic control.

Contraindications

Do not take Vildagliptin in the following cases:
- If you are allergic to vildagliptin or other excipients listed in subsection 6.1;
- If you have type 1 diabetes mellitus;
- if you have acute or chronic metabolic acidosis (including diabetic ketoacidosis - a complication accompanied by rapid weight loss, nausea or vomiting and/or lactoacidosis - excessive accumulation of lactic acid in the blood);
- if you have liver dysfunction with increased activity of "liver" enzymes - alanine aminotransferase (ALT) or aspartate aminotransferase (AST)) 3 or more times higher than normal);
- If you have New York Heart Association (NYHA) class IV functional class (FC) chronic heart failure;
- if you are under 18 years of age.

Usage

Type 2 diabetes mellitus is a condition in which the pancreas does not produce enough insulin or the body loses its sensitivity to it, resulting in high blood sugar (hyperglycaemia). The production of large amounts of glucagon can also lead to the development of this condition. Insulin is a substance (hormone) that helps lower blood glucose levels, especially after a meal, glucagon is a substance (hormone) that has the opposite effect (both of these hormones are produced by cells in the pancreas). Vildagliptin works by helping the pancreas to produce more insulin and less glucagon. The drug Vildagliptin helps to control blood glucose levels. It is important to take the drug against the background of recommended dietary therapy and exercise.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.